Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.

This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flu...

Full description

Bibliographic Details
Main Authors:	Ruszniewski, P, Ish-Shalom, S, Wymenga, M, O'Toole, D, Arnold, R, Tomassetti, P, Bax, N, Caplin, M, Eriksson, B, Glaser, B, Ducreux, M, Lombard-Bohas, C, de Herder, W, Delle Fave, G, Reed, N, Seitz, J, Van Cutsem, E, Grossman, A, Rougier, P, Schmidt, W, Wiedenmann, B
Format:	Journal article
Language:	English
Published:	2004

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.

Similar Items